Nicoya is a nanotechnology company developing sensor products that will change the world of biotechnology, life sciences, and healthcare.
Nicoya provides advanced analytical instruments for the biotechnology and pharmaceutical industries.
Nicoya was founded in 2012 by Ryan Denomme, alongside with Shawn Fitzpatrick. The company is headquartered in Kitchener, Ontario, Canada.
Nicoya's technology is based on the unique optical properties of nanomaterials, also called nanophotonics.
Nicoya uses a revolutionary nanosensing technology, which can detect a wide range of biomolecules at extremely small concentrations in a compact, low cost, rapid, and easy to use format.
Nicoya's first product is OpenSPR, is a powerful and affordable instrument for label-free interaction analysis. Interactions between proteins, antibodies, DNA, RNA, peptides, polymers, and more can be studied with nanoscale resolution.
Nicoya is backed by Whitecap Venture Partners, Garage Capital, MaRS IAF, Laurier Startup Fund, University of Waterloo Student Venture Fund, and others. The company raised $10M in a Series A financing on Jan 14, 2020. This brings Nicoya's total funding to $14.6M to date.